Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ALUR

Allurion Technologies Inc

May 15 • 02:26PM ET

1.89

Dollar change -0.22
Percentage change -10.43	%

Healthcare • Medical Devices • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF JSML

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.79	Insider Own	24.13%	Shs Outstand	47.69M	Perf Week	-10.85%
Market Cap	90.57M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.00%	Shs Float	36.36M	Perf Month	-19.92%
Income	-58.20M	PEG	-	EPS next Q	-0.24	Inst Own	19.12%	Short Float	1.45%	Perf Quarter	-35.49%
Sales	48.78M	P/S	1.86	EPS this Y	72.10%	Inst Trans	-8.35%	Short Ratio	0.51	Perf Half Y	-55.32%
Book/sh	-1.38	P/B	-	EPS next Y	26.05%	ROA	-72.92%	Short Interest	0.53M	Perf Year	-81.90%
Cash/sh	0.62	P/C	3.05	EPS next 5Y	-	ROE	-1715.20%	52W Range	1.56 - 10.94	Perf YTD	-49.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-82.72%	Beta	-0.10
Dividend TTM	-	Quick Ratio	0.72	Sales past 5Y	-5.58%	Gross Margin	75.38%	52W Low	21.15%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	0.81	EPS Y/Y TTM	-1544.19%	Oper. Margin	-174.51%	RSI (14)	43.31	Volatility	13.86% 11.50%
Employees	252	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-119.31%	Recom	1.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	126.30%	Payout	-	Rel Volume	0.15	Prev Close	2.11
Sales Surprise	2.02%	EPS Surprise	139.29%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	1.04M	Price	1.89
SMA20	-7.47%	SMA50	-14.39%	SMA200	-46.85%	Trades		Volume	118,319	Change	-10.43%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-24	Initiated	Jefferies	Buy	$5

Today 08:00AM	Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss (Business Wire) -10.43%
May-14-24 12:53PM	ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +8.76%
08:00AM	Allurion Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-02-24 08:00AM	Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey (Business Wire) -6.38%
Apr-30-24 08:30AM	Allurion Announces Preliminary First Quarter 2024 Results (Business Wire)
08:31AM	Loading…
Apr-17-24 08:31AM	Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments (Business Wire) -8.05%
Apr-04-24 08:00AM	Allurion Expands Virtual Care Suite to the United States (Business Wire) +78.03%
Mar-21-24 12:53PM	ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (Business Wire)
Mar-13-24 08:30AM	Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference (Business Wire) +6.04%
Mar-12-24 08:00AM	Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair (Business Wire)
Mar-04-24 08:30AM	Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024 (Business Wire) -8.31%
Feb-20-24 04:05PM	Allurion to Participate in Cowens 44th Annual Health Care Conference (Business Wire) +7.47%
Feb-08-24 08:30AM	Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference (Business Wire)
Jan-29-24 08:00AM	Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies (Business Wire)
09:04AM	Loading…
Jan-23-24 09:04AM	Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss (Business Wire)
08:15AM	World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss (Business Wire)
Jan-17-24 08:00AM	Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships (Business Wire)
Jan-11-24 08:00AM	Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities (Business Wire)
Jan-08-24 08:00AM	Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook (Business Wire)
Jan-05-24 08:00AM	New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program (Business Wire)
Jan-02-24 08:00AM	Allurions Digital Platform Gains Traction with Expanded Strategic Partnership (Business Wire) -5.61%
Nov-13-23 08:00AM	Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-06-23 04:05PM	Allurion to Participate in the Jefferies London Healthcare Conference (Business Wire) -7.08%
08:00AM	Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-11-23 08:00AM	Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon (Business Wire)
Oct-04-23 08:00AM	Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023 (Business Wire)
Sep-18-23 08:00AM	Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress (Business Wire) +8.00%
Aug-29-23 08:00AM	Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach (Business Wire)
Aug-28-23 08:00AM	Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress (Business Wire)
01:33PM	Loading…
Aug-04-23 01:33PM	Allurion sees tailwind from weight loss drug frenzy (Yahoo Finance)

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chardon Benoit	Chief Commercial Officer	Dec 12 '23	Option Exercise	1.19	165,539	197,562	199,183	Dec 14 07:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALUR

Allurion Technologies Inc

Upgrade your FINVIZ experience